USPTO Examiner CARR DEBORAH D - Art Unit 1691

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19315079S-BETA-HYDROXYBUTYRATE ESTERS FOR IMPROVING METABOLIC FUNCTIONAugust 2025January 2026Allow510NoNo
19207954SHORT CHAIN FATTY ACID COMPOUNDS AND USES THEREOFMay 2025December 2025Allow700NoNo
18892950REDUCING THE RISK OF VIRAL INFECTION DUE TO VIRAL CONTAMINATED FEEDSeptember 2024March 2025Allow610YesNo
18807247SYSTEM AND METHOD FOR TRIGLYCERIDE MANUFACTUREAugust 2024June 2025Allow1011YesNo
18776474MONOGLYCERIDE USE IN ANIMALSJuly 2024October 2025Allow1410NoNo
18774065MODULAR, MOBILE, AND AUTOMATED SOLVENT EXTRACTION AND DISTILLATION SYSTEMS, AND METHODS OF USING THE SAMEJuly 2024August 2025Allow1310NoNo
18745509COMPOSITIONS AND METHODS FOR MODULATING EQUINE FATTY ACID PROFILESJune 2024September 2025Allow1510NoNo
18610897IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLESMarch 2024June 2025Allow1521YesNo
18577214NOVEL COMBINATORIAL ANTITUMOR TREATMENT METHODS AND RELATED COMPOSITIONS, KITS, AND SYSTEMSJanuary 2024February 2025Allow1410NoNo
18537355COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF INFLAMMATORY, DEGENERATIVE, AND NEURODEGENERATIVE DISEASESDecember 2023October 2025Allow2320NoNo
18515464COMPOSITIONS AND METHODS FOR SOLIDIFIED FERMENTED ANIMAL FEEDNovember 2023February 2025Allow1500NoNo
18265491METHOD FOR PREPARING ACRYLIC ACIDJune 2023December 2025Allow3100NoNo
18038031PROCESS FOR PRODUCING ISOCYANATESMay 2023December 2025Allow3000NoNo
18250587PRODUCTION OF 2,2,4,4-TETRAMETHYLCYCLOBUTANE-1,3-DIOL FROM ISOBUTANOL USING A HOMOGENEOUS CATALYSTApril 2023October 2025Allow3000NoNo
18249984A METHOD FOR THE PREPARATION OF 1,2-PROPANEDIOLApril 2023October 2025Allow3000NoNo
18249982A METHOD FOR THE PREPARATION OF 1,2-PROPANEDIOLApril 2023February 2026Allow3410NoNo
18249695A METHOD FOR THE PREPARATION OF 1,2-PROPANEDIOLApril 2023October 2025Allow3000NoNo
18249729A PROCESS FOR PREPARING 1,2-PROPANEDIOL FROM PROPANEApril 2023September 2025Allow2900NoNo
18249660A METHOD FOR THE PREPARATION OF 1,2-PROPANEDIOLApril 2023September 2025Allow2900NoNo
18249724METHOD FOR THE PREPARATION OF 1,2-PROPANEDIOLApril 2023October 2025Allow3000NoNo
18296363IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLESApril 2023October 2025Allow3100NoNo
18130439PROCESS FOR SYNTHESIS OF FLUORINATED OLEFINSApril 2023September 2025Allow2900NoNo
18028001A PROCESS FOR THE SYNTHESIS OF ANTHRANILIC ACID/AMIDE COMPOUNDS AND INTERMEDIATES THEREOFMarch 2023February 2026Allow3510NoNo
18026610A PROCESS FOR THE SYNTHESIS OF ANTHRANILIC ACID/AMIDE COMPOUNDS AND INTERMEDIATES THEREOFMarch 2023February 2026Allow3510NoNo
18025527METHOD FOR PRODUCING COMPOUNDMarch 2023February 2026Allow3610NoNo
18023747PROCESS FOR PRODUCING ISOCYANATESFebruary 2023August 2025Allow3000NoNo
18111018METHOD OF PRODUCING ADIPIC ACIDFebruary 2023July 2025Allow2900NoNo
18110060METHOD FOR PURIFYING ACRYLIC ACID ESTER COMPOUNDFebruary 2023November 2025Allow3300NoNo
18040999ISOBUTANOL PRODUCTION PROCESSFebruary 2023August 2025Allow3000NoNo
18040992ETHANOL CONVERSION TO ISOBUTANOLFebruary 2023July 2025Allow2900NoNo
18018585DEVICE AND METHOD FOR PRODUCING METHANOL FROM CARBON DIOXIDEJanuary 2023August 2025Allow3100NoNo
18161619REDUCING THE RISK OF VIRAL INFECTION DUE TO VIRAL CONTAMINATED FEEDJanuary 2023July 2025Allow3010NoNo
18016198METHOD FOR PREPARING ESTER-BASED COMPOSITIONJanuary 2023February 2026Allow3710YesNo
18003460COLORLESS MONOCHLOROACETIC ACID AND THE METHOD OF PREPARATION THEREOFDecember 2022January 2026Allow3710YesNo
17791561METHOD FOR PREPARING ISOPROPYL ALCOHOLDecember 2022July 2025Allow3600NoNo
18008757Process for Recovering Oxidation By-ProductsDecember 2022January 2026Allow3710NoNo
18008312LIMITING ACETIC ACID PRODUCTION IN ETHANE ODH PROCESSDecember 2022January 2025Allow2600NoNo
18000539PROCESS FOR PURIFYING A MIXTURE OF DIOLSDecember 2022December 2025Allow3720NoNo
17928567PRODUCTION AND PURIFICATION OF ACETIC ACIDNovember 2022December 2025Allow3710NoNo
17926301AGENT FOR INDUCING REGRESSION OF TRIGLYCERIDE DEPOSIT ATHEROSCLEROSISNovember 2022January 2026Allow3810NoNo
17926107METHOD FOR PREPARING ACRYLIC ACID FROM BETA-PROPIOLACTONENovember 2022July 2025Allow3200NoNo
17925812Use of 4-Phenylbutyric Acid and/or 3-Phenylbutyric Acid and/or 2-Phenylbutyric Acid in Preventing and Treating Cryptogamic DiseasesNovember 2022February 2026Abandon3920NoNo
17998891MCT FORMULATIONS FOR IMPROVING COGNITIVE FUNCTIONSNovember 2022November 2025Allow3610NoNo
17924373SYSTEM AND METHOD FOR CONTINUOUSLY PRODUCING DIETHYL METHYLPHOSPHONITENovember 2022October 2025Allow3510NoNo
17918339PERSONAL CARE COMPOSITION WITH VISUALLY DISTINCT AQUEOUS AND OIL PHASEOctober 2022August 2025Allow3400NoNo
17907368NOVEL CATIONIC LIPID HAVING CYSTINE SKELETONSeptember 2022March 2026Allow4201NoNo
17914086METHOD OF FRACTIONATION OF FATTY ACIDS WITH A DIFFERENCE OF TWO CARBONS BY MOLECULAR DISTILLATIONSeptember 2022November 2025Allow3810NoNo
17800758PROCESS FOR MAKING SOLID METHYLGLYCINE DIACETATE ALKALI METAL SALTSAugust 2022October 2025Abandon3810NoNo
17758759TREATMENT OF LATE-ONSET NEURODEGENERATIVE DISEASES IN HETEROZYGOUS NPC1 GENE MUTATION CARRIERSJuly 2022December 2025Allow4110NoNo
17787611CO-CRYSTAL OF KETOPROFEN AND ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USES THEREOFJune 2022August 2025Allow3810NoNo
17787934EDIBLE OIL/FAT IN WHICH CONTENT OF GLYCIDOL AND GLYCIDOL FATTY ACID ESTER ARE REDUCED, AND METHOD FOR MANUFACTURING SAID EDIBLE OIL/FATJune 2022August 2025Allow3810NoNo
17787519A TOPICAL ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITION COMPRISING ZILEUTONJune 2022November 2025Allow4110NoNo
17787541ANHYDROUS COMPOSITION FOR CARING FOR KERATIN MATERIALSJune 2022September 2025Allow3910NoNo
17783770BIOMOLECULE FOR TREATMENT OF CORNEAL PATHOLOGIESJune 2022December 2025Abandon4210NoNo
17830378LOW IRON HYDROUS PHOSPHOLIPID AND METHOD FOR SEPARATING LOW-IRON HYDROUS PHOSPHOLIPIDS FROM SOYBEAN OIL SEDIMENTSJune 2022August 2025Allow3910NoNo
17779904INSULIN SECRETION-PROMOTING AGENT AND BLOOD SUGAR LEVEL IMPROVER USING SAME, DIABETES IMPROVER, AND FOODMay 2022September 2025Allow4010NoNo
17778786COMBINATION CANNABINOID-PHENYLETHANOID FORMULATION FOR TREATMENT OF INFLAMMATION AND METHODS RELATED THERETOMay 2022November 2025Allow4210NoNo
17777897ACTIVE COMPOUND COMBINATIONS COMPRISING FATTY ACIDSMay 2022August 2025Allow3910NoNo
17777402Processes for the Preparation of Alpha-Hydroxy Esters via Grignard Coupling and Thiolation ReactionsMay 2022September 2025Allow4020NoNo
17755498GUT-PROTECTIVE COMPOSITIONS COMPRISING BOSWELLIC ACIDApril 2022November 2025Abandon4310NoNo
17771601SOLID STATE FORMS OF FEZAGEPRAS AND PROCESS FOR PREPARATION THEREOFApril 2022January 2026Allow4510NoNo
17771139Compositions and Methods Related to Organic OxidesApril 2022October 2025Allow4110NoNo
17765900METHOD OF PREPARATION WHITE EMULSIFIED SCENTED CROCODILE OILApril 2022November 2025Abandon4310NoNo
17765986METHOD FOR PREPARING ALKENYL AMINOBORANES AND THEIR DERIVATIVES, AND USES THEREOFApril 2022December 2025Abandon4510NoNo
17763463PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SARCOPENIA CONTAINING NON-NATURAL AMINO ACID DERIVATIVEMarch 2022December 2025Abandon4410NoNo
17762520PROCESS FOR THE DISTILLATION OF ISOCYANATESMarch 2022September 2025Allow4210NoNo
17760778SOLIDIFICATION OF HEXYL 2-[4-(DIETHYLAMINO)-2-HYDROXYBENZOYL]BENZOATEMarch 2022August 2025Allow4110NoNo
17753693PREVENTION OF MCPD FORMATION IN TRIACYLGLYCERIDE OILSMarch 2022November 2025Abandon4410NoNo
17640419METHOD FOR PRODUCING ISOCYANATESMarch 2022August 2025Allow4210NoNo
17640024REACTOR TUBE ASSEMBLYMarch 2022August 2025Allow4110NoNo
17639751METHOD FOR PRODUCING HALOGENATED CARBONYLMarch 2022July 2025Allow4110NoNo
17637905METHOD FOR PRODUCING ISOCYANATE COMPOUNDFebruary 2022February 2025Allow3600NoNo
17673086Microemulsion Delivery Systems for Water-Based BeveragesFebruary 2022November 2025Allow4510NoNo
17619374Method Of Producing A Low Glycidol Monoglyceride Composition And The Low Glycidol Monoglyceride Composition As SuchDecember 2021November 2025Allow4710NoNo
17611886FRAGRANCE OR FLAVOUR MIXTURENovember 2021January 2026Allow5020NoNo
17518822BIOBASED GLYCERYL HEPTANOATE ESTER COMPOSITIONS AND METHODS OF MAKING AND USING THE SAMENovember 2021July 2025Allow4511YesNo
17608720TREATMENT OF DIABETESNovember 2021September 2025Allow4620YesNo
17594776Pet Food Compositions Comprising Caprylic Acid and Docosahexaenoic Acid and/or Eicosapetaenoic Acid for Use in Treating Struvite UrolithiasisOctober 2021July 2025Allow4510NoNo
17607300EXTRACTING AND REFINING PLANT CUTICULAR WAXES FROM AQUEOUS DISPERSION USING TEMPERATURE AND PH ADJUSTMENTOctober 2021November 2024Allow3720NoNo
17594629COMPOSITION CONTAINING CREATINE FATTY ESTER FOR USE IN MEDICINEOctober 2021May 2025Allow4310NoNo
17601289VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS, ELOVANOID HYDROXYLATED DERIVATIVES, AND METHODS OF USEOctober 2021August 2025Allow4710NoNo
17487047CRYSTALLINE FORM A OF 2, 2-BIS(4-FLUOROPHENYL)-2-PHENYLACETAMIDE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOFSeptember 2021December 2024Allow3810NoNo
17441807NEAR-INFRARED-ABSORBING COMPOSITION, NEAR-INFRARED-ABSORBING FILM, AND IMAGE SENSOR FOR SOLID-STATE IMAGING ELEMENTSeptember 2021August 2025Allow4710NoNo
17414559THERAPEUTIC, PREVENTIVE, OR IMPROVEMENT AGENT FOR INFLAMMATORY DISEASE AND ALLERGIC DISEASESeptember 2021December 2024Allow4210NoNo
17438548DALCETRAPIB IN THE TREATMENT OF SICKLE CELL TRAITSeptember 2021August 2025Allow4710NoNo
17428509LEVODOPA DERIVATIVE AND USE THEREOFAugust 2021March 2025Abandon4310NoNo
17428327ACTIVE AGENTS FOR SKIN AND HAIR CARE WITH PHYSICOCHEMICAL MODIFYING PROPERTIESAugust 2021December 2024Allow4110NoNo
17427903Composition for Treatment and / or Prevention of Infectious Hoof DiseasesAugust 2021June 2025Abandon4610NoNo
17426319KETONE BODY PRODUCTION PROMOTING COMPOSITIONJuly 2021April 2025Abandon4410NoNo
17425746Topical Gel Compositions of NaproxenJuly 2021December 2024Allow4010NoNo
17309559CANNABINOID COMPOSITIONS WITH HIGH SOLUBILITY AND BIOAVAILABILITYJune 2021February 2025Abandon4410NoNo
17238345MODULAR, MOBILE, AND AUTOMATED SOLVENT EXTRACTION AND DISTILLATION SYSTEMS, AND METHODS OF USING THE SAMEApril 2021February 2025Allow4611NoNo
17282185THERAPEUTIC COMPOSITIONSApril 2021November 2024Allow4411NoNo
17175601PROCESS SUPPORTED BY EQUIPMENT GROUP FOR EXTRACTING COMPOUNDS FROM BOTANICALSFebruary 2021January 2025Allow4711NoNo
16968051EDIBLE OIL REFININGAugust 2020June 2024Allow4620NoNo
16843680METHOD AND APPARATUS FOR EXTRACTING BOTANICAL OILSApril 2020September 2025Abandon6020NoYes
16606739THE NEW USE OF 2-[(3Z)-6-FLUORO-2-METHYL-3-[(4-METHYLSULFINYLPHENYL) METHYLIDENE]INDEN-1 -YL] ACETIC ACIDOctober 2019November 2025Allow6090YesNo
16575125NAPHTHALENEDICARBOXYLIC ACID DICHLORIDE PRODUCTION METHODSeptember 2019March 2020Allow600NoNo
16288353METHODS FOR REDUCING SOAP FORMATION DURING VEGETABLE OIL REFININGFebruary 2019January 2020Allow1010NoNo
16329120METHOD FOR PREPARING SINGLE CRYSTAL OF ANHYDROUS HALOGENATED CHOLINE OR DERIVATIVE THEREOFFebruary 2019January 2020Allow1000NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CARR, DEBORAH D.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
2
Examiner Affirmed
1
(50.0%)
Examiner Reversed
1
(50.0%)
Reversal Percentile
70.2%
Higher than average

What This Means

With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
8
Allowed After Appeal Filing
6
(75.0%)
Not Allowed After Appeal Filing
2
(25.0%)
Filing Benefit Percentile
93.9%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 75.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner CARR, DEBORAH D - Prosecution Strategy Guide

Executive Summary

Examiner CARR, DEBORAH D works in Art Unit 1691 and has examined 223 patent applications in our dataset. With an allowance rate of 96.0%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 19 months.

Allowance Patterns

Examiner CARR, DEBORAH D's allowance rate of 96.0% places them in the 86% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CARR, DEBORAH D receive 1.08 office actions before reaching final disposition. This places the examiner in the 11% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CARR, DEBORAH D is 19 months. This places the examiner in the 94% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +4.1% benefit to allowance rate for applications examined by CARR, DEBORAH D. This interview benefit is in the 28% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 37.5% of applications are subsequently allowed. This success rate is in the 85% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 54.5% of cases where such amendments are filed. This entry rate is in the 80% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 2% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 77.8% of appeals filed. This is in the 69% percentile among all examiners. Of these withdrawals, 57.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 41.0% are granted (fully or in part). This grant rate is in the 32% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 6.7% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.9% of allowed cases (in the 60% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.